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Heart Failure
eta-Blocker Use and Outcomes
mong Hospitalized Heart Failure Patients
aved Butler, MD,* James B. Young, MD,† William T. Abraham, MD,‡ Robert C. Bourge, MD,§
irkwood F. Adams, JR, MD, Robert Clare, MS,¶ Christopher O’Connor, MD,#
or the ESCAPE Investigators
ashville, Tennessee; Cleveland and Columbus, Ohio; Birmingham, Alabama; and Chapel Hill and
urham, North Carolina
OBJECTIVES The purpose of this study was to determine the effect of beta-blocker therapy on outcomes of
hospitalized heart failure (HF) patients enrolled in the Evaluation Study of Congestive Heart
Failure and Pulmonary Artery Catheterization (ESCAPE).
BACKGROUND The effect of beta-blocker therapy on outcomes among hospitalized HF patients is not well
documented.
METHODS We studied the association between beta-blocker therapy and outcomes among 432
hospitalized HF patients in the ESCAPE trial.
RESULTS A total of 268 patients (62%) were on beta-blockers before admission. These patients had a
shorter length of stay (7.9  6.3 days vs. 9.4  6.7 days; p  0.01) and a lower six-month
mortality rate (16% vs. 24%; p  0.03) compared with those who were not on beta-blockers.
Of the patients who were on admission beta-blockers and were discharged alive (n  263),
beta-blockers were discontinued in 54 and significantly modified (50% dose reduction or
changed to alternative beta-blocker) in 28 patients during hospitalization. Factors associated
with discontinuation of beta-blockers during hospitalization included respiratory rate 24
breaths/min (30.8% vs. 16.9%; p  0.03), heart rate 100 beats/min (19.2% vs. 7.3%; p 
0.01), lower ejection fraction (17.9  5.4% vs. 20.2  7.1%; p  0.04), diabetes (21.2% vs.
37.1%; p  0.03), and systolic blood pressure 100 mm Hg during hospitalization (70.3%
vs. 54.1%; p  0.03). After adjusting for factors associated with beta-blocker use and those
with outcomes, consistent beta-blocker use during hospitalization was associated with a
significant reduction in the rate of rehospitalization or death within six months after discharge
(odds ratio 0.27, 95% confidence interval 0.10 to 0.71; p  0.01).
CONCLUSIONS Beta-blocker therapy before and during hospitalization for HF is associated with improved
outcomes. (J Am Coll Cardiol 2006;47:2462–9) © 2006 by the American College of




















ultiple clinical trials have demonstrated that beta-blocker
herapy improves morbidity and mortality among patients
ith heart failure (HF) and reduced ejection fraction (EF)
1–5). However, these studies were done on optimally
iuresed patients mostly in the outpatient setting. How best
o manage beta-blocker therapy among hospitalized patients
ith decompensated HF is not well known. Studies ad-
ressing beta-blocker use among hospitalized HF patients
rospectively have primarily studied the safety of beta-
locker initiation before discharge in patients who were
lready adequately treated and were ready to be discharged
6,7). Although most experts would agree not to initiate
eta-blocker therapy in patients with decompensated HF,
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Manuscript received November 5, 2005; revised manuscript received January 24,
006, accepted February 7, 2006.here is no consensus on what to do with beta-blockers for
atients already on chronic therapy who present with fluid
verload. Continuing these drugs may worsen congestion
wing to their negative inotropic properties; however, dis-
ontinuing beta-blocker therapy may lead to a higher risk of
rrhythmia and complications. More importantly, re-
nitiation and up-titration of therapy is likely to be difficult
nd may be an impediment in long-term therapy with
ecommended doses. The impact of beta-blocker therapy on
utcomes among hospitalized patients with decompensated
F is an important and unanswered question. Using data
rom patients enrolled in the Evaluation Study of Conges-
ive Heart Failure and Pulmonary Artery Catheterization
ESCAPE) (8), we investigated the differences in clinical
haracteristics and outcomes of patients admitted to the
ospital with decompensated HF in whom beta-blocker ther-
py was continued compared with those in whom it was not.
ETHODS
atient population. Patients enrolled in the ESCAPE
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June 20, 2006:2462–9 Beta-Blocker Use in Decompensated HFherapy among hospitalized HF patients. The study design
nd results of the ESCAPE trial have been published (8).
he ESCAPE trial assessed pulmonary artery catheter
PAC) use among patients admitted with decompensated
F. Patients were randomly assigned to receive care with
AC placement and hemodynamic guidance or clinical
anagement without hemodynamic monitoring. Data col-
ected included admission signs and symptoms, physical
xamination findings, laboratory values, hemodynamics (in
he PAC arm), medication use (before admission, during
ospitalization, and at discharge), complications, length of
tay, and outcomes up to 180 days after discharge.
tudy design. The impact of beta-blocker therapy on
utcomes among patients taking or not taking beta-blockers
efore admission and among those who were or were not
rescribed beta-blockers at discharge was studied. The goal
f this post-hoc analysis of the ESCAPE trial, however, was
o study the impact of beta-blocker therapy during hospi-
alization. To identify the patients in whom beta-blocker
herapy was continued or discontinued during hospital stay,
e identified 268 of the 432 patients in the ESCAPE trial
n preadmission beta-blocker therapy. Of these, four pa-
ients died during the initial hospitalization, and there was
o information on discharge beta-blocker status for one
atient. These five patients were excluded from this analysis.
f the remaining 263 patients on preadmission beta-
locker therapy, 209 patients (79%) were discharged on
eta-blockers. These patients were compared with the 54
atients in whom beta-blocker therapy was not prescribed at
ischarge and was discontinued during hospitalization.
utcomes. Outcomes studied among these patients in-
luded need for ventilator or intra-aortic balloon pump sup-
ort, need for cardiopulmonary resuscitation, length of stay,
ortality rate during the index hospitalization, 180-day mor-
ality, rehospitalization, and death or rehospitalization rates.
tatistical analysis. Three separate sets of analyses were
erformed: 1) among patients on (n  268) and not on
n  164) beta-blockers at the time of admission; 2) among
atients on beta-blockers at admission and those in whom
eta-blockers were continued (n  209) and discontinued
n  54) during hospitalization; and 3) among those who
ere (n  241) and were not prescribed (n  182)
Abbreviations and Acronyms
BUN  blood urea nitrogen
CI  confidence interval
EF  ejection fraction
ESCAPE  Evaluation Study of Congestive
Heart Failure and Pulmonary
Artery Catheterization
HF  heart failure
HR  hazard ratio
OR  odds ratio
PAC  pulmonary artery catheter
PCWP  pulmonary capillary wedge pressureeta-blockers at discharge. cFor the analysis on the group of patients on beta-blockers
t admission and whether therapy was continued or discon-
inued during hospitalization, two separate sets of analyses
ere performed. It is possible that preadmission beta-
locker therapy may have been discontinued during hospi-
alization and then re-initiated at discharge. Therefore the
resence of beta-blockers on admission and discharge does
ot guarantee continuous use. In order to take this into
ccount, we identified 28 patients who were either on 50%
f the dose of the same beta-blocker at discharge compared
ith preadmission dose (assuming that beta-blockers were
iscontinued initially and re-initiated at lower doses) or on
ifferent beta-blockers at admission and discharge. Two sets
f analyses were performed, either including these patients
n the beta-blocker therapy arm (assuming continued ther-
py) or including them in a broader category of patients in
hom beta-blocker therapy was disrupted (modified or
iscontinued). These 28 patients did not affect the overall
esult with respect to end points, and only data from the
ormer analysis are shown.
Patient characteristics and outcomes were compared us-
ng chi-square tests for categoric and t tests for continuous
ariables. When the assumption of normality for the t test
as violated, the Wilcoxon rank-sum test was used instead.
hen expected cell frequencies were too low for the
hi-square test, the Fisher exact test was used instead.
ontinuous variables are presented as mean  standard
eviation. Categoric data are presented as frequencies and
ercentages. Hemodynamic data were available on only 215
atients, because half of the patients were randomly assigned to
eceive medical therapy without PAC. Hemodynamic data
ere studied descriptively but not in the adjusted analyses.
Unadjusted risks for adverse outcomes were assessed and
djusted using multivariable logistic regression analysis for a
omposite propensity score for beta-blocker use and for a
ropensity score as well as individual variables that were
redictive of various outcomes. Variables associated with the
se of beta-blockers were identified based on: 1) clinical
onsiderations; 2) an apparent relation with beta-blocker
se; and 3) a reasonable number of non-missing values. The
esulting subset included the following variables: age, atrial
brillation, supine heart rate, ejection fraction (EF), creat-
nine, blood urea nitrogen (BUN), hematocrit, and in-
ospital hypotension (systolic blood pressure 100
m Hg). A logistic model was then fit to describe the effect
f these confounding influences on beta-blocker use, and
he propensity score was defined as the quintile of risk
predicted value) associated with a given configuration of
hese potential confounders in that model. Each end point
as first analyzed with an “unadjusted” logistic model (with
ischarge beta-blocker use as the only predictor). Subse-
uently, propensity score was added in an “adjusted model.”
inally, after examining the previous model for interaction
etween beta-blocker use and propensity score, other known
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Beta-Blocker Use in Decompensated HF June 20, 2006:2462–9Along with propensity score-adjusted analysis, to account
or the fact the sicker patients may have preferentially had
eta-blockers discontinued and that these patients had
ostly adverse outcomes we did a separate analysis after
xcluding the top 10% of patients with respect to heart rate
nd respiratory rate (as surrogate measures of severity of
isease). The results overall did not change (data not
hown). In fact, removing the patients who discontinued
eta-blockers and were above the 90th percentile for either
eart rate or respiratory rate did not only fail to reverse the
rend toward improved outcomes among patients dis-
harged on beta-blockers, it trended toward enhancing it.
Patients who died during the hospitalization were excluded,
ecause they were not classifiable by the study definition, i.e.,
se of beta-blockers at admission and at discharge. However,
his raises the possibility of selection bias, that only the patients
estined to do well were included in the study. To address this
able 1. Baseline Characteristics With Respect to Preadmission B
Patient Characteristics Overall (n 
ge (mean  SD), yrs 56.0  14
emale (%) 25.9
hite (%) 59.5
irst half of trial (%) 50.0
ystolic blood pressure (mean  SD), mm Hg 106.0  16
eart rate (mean  SD), beats/min 82.0  16
ulse rate 100 beats/min (%) 11.5




Atrial fibrillation (%) 30.2
Stroke or transient ischemic attack (%) 12.4
Myocardial infarction (%) 44.2
igns and symptoms
Dyspnea at rest or on exertion (%) 98.8
S3 gallop (%) 65.7
Increased jugular venous pressure (%) 94.4
Rales (%) 52.3
Respiratory rate 24 breaths/min (%) 20.7
Peripheral edema (%) 68.1
aboratory results
Sodium (mean  SD), mmol/l 136.6  4.4
Sodium 135 mmol/l (%) 24.0
Creatinine (mean  SD), mmol/l 1.5  0.6
Blood urea nitrogen (mean  SD), mmol/l 34.8  22
Hemoglobin (mean  SD), mg/dl 13.4  14
edications
ACE inhibitors or ARB (%) 89.3




emodynamic characteristics (PAC arm) n  215
Right atrial pressure, mm Hg 14  10
Pulmonary artery systolic pressure, mm Hg 55  14
Pulmonary wedge pressure, mm Hg 25  9
Cardiac output, l/min 3.9  1.4
Cardiac index, l/min/m2 2.0  0.6Fisher exact test used. †Wilcoxon rank-sum test used.
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; PAC ssue, two sets of additional analyses were performed to assess
he impact of in-hospital deaths on outcomes by assuming
hat: 1) all patients who died during the index hospitalization
ere continued on beta-blockers; and 2) all these patients were
aken off their beta-blockers.
Odd ratios (OR) and 95% confidence intervals (CI) were
alculated for discrete end points, and the hazard ratio (HR)
as calculated for the continuous end points. Statistical
ignificance was based on an empirical alpha level of 0.05 in
ll hypothesis tests. All analyses were done using SAS
ersion 8.2 (SAS Institute, Cary, North Carolina).
ESULTS
atient characteristics. Baseline patient characteristics are
escribed in Table 1. The average age of the study popula-
ion was 56  14 years with a mean EF of 19.4  6.8%.
Blocker Therapy
Beta-Blockers on Admission
p ValueNo (n  164) Yes (n  268)




106.0  17.0 105.0  16.0 0.59†
85.0  14.0 81.0  16.0 0.001†
14.1 9.9 0.18












136.4  4.7 136.8  4.2 0.35†
29.5 20.7 0.04
1.5  0.6 1.5  0.6 0.83†
35.4  23.6 34.5  22.1 0.96†






n  75 n  140
14  8 13  11 0.07†
57  14 54  14 0.15
27  9 24  9 0.02†
3.6  1.1 4.1  1.5 0.04†
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June 20, 2006:2462–9 Beta-Blocker Use in Decompensated HFpproximately 60% of the patients were white and 75%
ere male. Nearly 90% of the patients were on either
ngiotensin-converting enzyme inhibitors or angiotensin-
eceptor blocker therapy. Average serum sodium concentra-
ion was 137  4 mmol/l, and mean serum creatinine
oncentration was 1.5  0.6 mmol/dl.
eta-blocker use. Two hundred sixty-eight patients (62%)
ere on beta-blockers at admission. The most common
eta-blockers were carvedilol (n  155) and metoprolol
n  84). Of the 263 patients on preadmission beta-
lockers who were discharged alive (and medication infor-
ation on discharge was complete), 209 were prescribed
eta-blockers at discharge; the other 54 were not.
utcomes. The average length of stay was 8.5  6.4 days.
ight patients (2%) died during the index hospitalization, 21
4.9%) died during or within 30 days of the index hospitaliza-
ion, and 83 (19.2%) died within 180 days. A total of 247
atients (57.1%) required rehospitalization within 180 days.
eta-blocker use and outcomes. PREADMISSION BETA-
LOCKER USE. Table 1 summarizes the characteristics of
hose patients who were and were not on beta-blocker therapy
efore admission. Beta-blocker use was significantly higher
mong whites, patients randomized during the second half of
he trial, and those with a history of neurologic events. Patients
n beta-blockers were less likely to have edema on exam, to be
yponatremic, or to be on antiarrhythmic therapy. The average
eart rate was lower for patients on beta-blocker therapy
80.5  16.3 beats/min vs. 85.1  14.3 beats/min; p  0.001).
or patients in whom hemodynamic data were available (n 
15), patients not on beta-blockers at admission (n  75) had
higher pulmonary capillary wedge pressure (PCWP) (27  9
m Hg vs. 24  9 mm Hg; p  0.02) and lower cardiac index
1.8  0.5 l/min/m2 vs. 2.1  0.7 l/min/m2; p  0.03).
Patients on preadmission beta-blocker therapy had a
horter length of stay (7.9  6.3 days vs. 9.4  6.7 days;
 0.003), and lower 180-day mortality rate (16.0% vs.
4.4%; p  0.03). When these outcome analyses were
djusted for differences in patient characteristics associated
ith baseline beta-blocker use and overall predictors of
ortality (detailed data not shown), there was a trend
oward lower 180-day mortality with preadmission beta-
locker therapy (OR 0.58, 95% CI 0.32 to 1.06; p  0.08).
Five of the eight patients who required cardiopulmonary
esuscitation, two of the six patients who required intraaor-
ic balloon pump insertion, and five of the eight patients
ho required mechanical ventilation during the index hos-
italization were among those patients who were not on
eta-blocker therapy before admission (all p  0.20).
ETA-BLOCKER USE DURING HOSPITALIZATION. Table 2
hows the differences in characteristics among those patients
ho were on beta-blocker therapy at both admission and
ischarge versus those in whom beta-blocker therapy was
iscontinued before discharge. Patients in whom beta-
locker therapy was discontinued significantly differed from
hose in whom it was continued in the following character- Pstics: respiratory rate 24 breaths/min (30.8% vs. 16.9%;
 0.03), heart rate 100 beats/min (19.2% vs. 7.3%;
 0.01), lower EF (17.9  5.4% vs. 20.2  7.1%; p 
.04), diabetes (21.2% vs. 37.1%; p  0.03), and hypoten-
ion (systolic blood pressure 100 mm Hg) during hospi-
alization (70.3% vs. 54.1%; p  0.03). Where data were
vailable (n  134), there were no significant differences in
ny of the hemodynamic measures among patients in whom
eta-blocker therapy was continued (n  104) and those in
hom it was discontinued (n  30). These included right
trial pressure of 13  7 mm Hg vs. 12  10 mm Hg (p 
.17), pulmonary wedge pressure of 25  9 mm Hg vs.
3  9 mm Hg (p  0.14), and a cardiac index of 2.0  0.6
/min/m2 vs. 2.1  0.6 l/min/m2 (p  0.43) among those
ho were not versus those who were on continued beta-
locker therapy, respectively.
Patients in whom beta-blocker therapy was continued had a
ower 180-day rehospitalization and death rate (59.8% vs.
4.1%; p  0.053). A full logistic propensity model for
eta-blocker use in this subset of patients (C-index  0.069)
as based on age, supine heart rate, serum sodium, BUN,
ematocrit, and creatinine concentrations, randomization in
he first or second half of study, atrial fibrillation, EF, antiar-
hythmic use, and in-hospital hypotension (systolic blood
ressure 100 mm Hg). As shown in Table 3, when data were
djusted for the resulting propensity score for beta-blocker
rescription and for the variables associated with outcomes,
ontinued beta-blocker use was associated with an improved
80-day rehospitalization rate (OR 0.45, 95% CI 0.19 to 1.03;
 0.048) and 180-day rehospitalization or death rate (OR
.27, 95% CI 0.10 to 0.71; p  0.01).
All four patients who required intra-aortic balloon pump
nsertion were among those in whom beta-blocker therapy was
iscontinued. One patient requiring mechanical ventilation
uring hospitalization remained on beta-blocker therapy.
MPACT OF IN-HOSPITAL DEATHS. There were eight deaths
uring the index hospitalization. Four of these were in
atients who were continued on beta-blocker therapy and
our who were not. Therefore, 4 of 268 patients on
dmission beta-blocker therapy (1.5%) died compared with
our of 164 (2.4%) of those not on beta-blocker therapy
p  0.48). Of the patients who were on beta-blockers on
dmission, when these four deaths were considered in the
roup that did not continue beta-blockers, the outcomes
ere in favor of continued beta-blocker therapy (59.8% vs.
5.9%; p  0.02; OR 0.22 [95% CI 0.08 to 0.60]; p  0.01
djusted). When these deaths were included in the group
ho were continued on beta-blocker therapy, the overall
utcomes still were in favor of beta-blocker therapy (60.6%
s. 74.1; p  0.06; OR 0.27 [95% CI 0.11 to 0.72]; p 
.01 adjusted).
ETA-BLOCKER PRESCRIPTION AT DISCHARGE. Among
he entire group of patients who were discharged alive (n 
23), 241 (57%) were discharged on beta-blocker therapy.
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Beta-Blocker Use in Decompensated HF June 20, 2006:2462–9ischarge included randomization in the second half of the
rial (57% vs. 41%, p  0.001), baseline heart rate (81  16
eats/min vs. 84  15 beats/min; p  0.02), BUN (32  20
s. 37  23; p  0.02), hematocrit (37  5% vs. 38  6%;
 0.05), EF (20  7% vs. 19  6%; p  0.03), and serum
odium (137  4 mmol/l vs. 136  5 mmol/l; p  0.03).
Patients discharged on beta-blocker therapy had a signifi-
antly lower 180-day death or rehospitalization rate (59% vs.
9%; p  0.048). This relation remained significant when data
ere adjusted for propensity to use beta-blocker at discharge
nd covariates associated with death or rehospitalization (OR
.51, 95% CI 0.27 to 0.97).
ISCUSSION
here are no clear guidelines on how to manage beta-
able 2. Baseline Characteristics of Patients on Preadmission Bet
Patient Characteristics Overall (n 
ge (mean  SD), yrs 55.0  14
emale (%) 26.2
hite (%) 64.3
irst half of trial (%) 46.0
ystolic blood pressure (mean  SD), mm Hg 105.0  16
eart rate (mean  SD), beats/min 81.0  16
ulse rate 100 beats/min (%) 9.7




Atrial fibrillation (%) 28.5
Stroke or transient ischemic attack (%) 14.6
Myocardial infarction (%) 44.7
igns and symptoms
Dyspnea at rest or on exertion (%) 98.1
S3 gallop (%) 65.0
Increased jugular venous pressure (%) 93.3
Rales (%) 48.3
Respiratory rate 24 breaths/min (%) 19.7
Peripheral edema (%) 63.9
aboratory results
Sodium (mean  SD), mmol/l 137.0  4.0
Sodium 135 mmol/l (%) 20.4
Creatinine (mean  SD), mmol/l 1.5  0.6
Blood urea nitrogen (mean  SD), mmol/l 33.7  20
Hemoglobin (mean  SD), mg/dl 12.1  9.7
edications
ACE inhibitors or ARB (%) 89.7




emodynamic characteristics (PAC arm) n  124
Right atrial pressure, mm Hg 13  9
Pulmonary artery systolic pressure, mm Hg 54  15
Pulmonary wedge pressure, mm Hg 24  9
Cardiac output, l/min 4.0  1.4
Cardiac index, l/min/m2 2.1  0.6
Fisher exact test used. †Wilcoxon rank-sum test used.
Abbreviations as in Table 1.locker therapy in patients with decompensated HF. All the (ajor studies that have assessed beta-blocker use among HF
atients were conducted among patients either in the
utpatient setting or during hospitalization after patients
ad been adequately diuresed and were deemed ready for
ischarge (1–7). Although theoretical justifications may be
ossible for continuation or discontinuation of beta-blocker
herapy on admission among hospitalized HF patients,
carce data exist comparing the two approaches. A second-
ry analysis of the Outcomes of a Prospective Trial of
ntravenous Milrinone for Exacerbations of Chronic Heart
ailure (OPTIME-CHF) study by Gattis et al. (9) sug-
ested that beta-blocker discontinuation during hospitaliza-
ion was associated with a higher mortality rate after
ischarge within 60 days. Similarly, a retrospective analysis
f the Flolan International Randomized Survival Trial
ockers Stratified by Beta-Blocker Use During Hospitalization
Beta-Blockers Continued
p ValueNo (n  54) Yes (n  209)




103.0  14.0 106.0  16.0 0.23†
83.0  18.0 80.0  16.0 0.22†
19.2 7.3 0.01












136.0  4.0 137.0  4.0 0.17†
24.5 19.3 0.40
1.5  0.6 1.5  0.6 0.79†
34.1  19.6 33.7  21.4 0.52†






n  30 n  94
13  7 12  10 0.17†
53  12 55  15 0.59
25  9 23  9 0.14
3.8  1.3 4.1  1.4 0.22†
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June 20, 2006:2462–9 Beta-Blocker Use in Decompensated HFeta-blocker use at randomization and reported no excess
isk for patients treated with beta-blockers at the time of
ospital presentation (10). In this investigation, we assessed
his issue using the ESCAPE trial database and found that
ontinuation of beta-blocker therapy, even after adjusting
or potential confounders associated with beta-blocker use
r the outcomes studied, was associated with a lower
ortality and rehospitalization rate subsequent to discharge.
Beta-blocker therapy before admission and after dis-
harge was also associated with better outcomes, and posi-
ive results were seen with continued beta-blocker therapy
uring hospitalization. Although these data are encourag-
ng, they need to be interpreted with caution. It is possible
hat discontinuation of beta-blocker therapy in a certain
roup of hospitalized HF patients may be related to worse
F or other medical reasons, which in turn may be
esponsible for poor outcomes among these patients rather
han lack of beta-blocker use. Patients in whom beta-
lockers were discontinued were more tachycardic and
achypneic on admission, had lower EF, and were more
ikely to develop hypotension during hospitalization.
mong patients in whom PAC data were available, PCWP
as higher (27  9 mm Hg vs. 24  9 mm Hg; p  0.02)
nd cardiac index was lower (1.8  0.5 l/min/m2 vs. 2.1 
.7 l/min/m2; p  0.03) among those who were not on
eta-blocker therapy at admission, although no statistically
ignificant hemodynamic differences were noted based on
hether or not beta-blockers were continued during hospi-
alization. Except for extreme hemodynamic alterations
uch as cardiogenic shock, the decision to discontinue
eta-blocker therapy among these patients was based pri-
arily on clinical judgment likely influenced by the provid-
r’s experience and bias. Many patients with similar hemo-
ynamics are routinely placed on beta-blocker therapy,
specially those awaiting transplantation. In our study,
mproved outcomes with continued beta-blocker therapy
ersisted after controlling for factors associated with the
ecision to discontinue beta-blocker therapy or those asso-
able 3. Unadjusted and Adjusted Outcomes Based on
eta-Blocker Use During Hospitalization
Chi-Square OR (95% CI) p Value
ehospitalization
Unadjusted 1.2 0.70 (0.38–1.31) 0.27
Adjusted*† 3.6 0.45 (0.19–1.03) 0.048
ehospitalization or death
Unadjusted 3.7 0.52 (0.27–1.02) 0.053
Adjusted*‡ 7.1 0.27 (0.10–0.71) 0.01
Propensity score for beta-blocker use: the full propensity model for beta-blocker use
n this subset of patients (C-Index  0.69) was based on age, heart rate, serum
odium, blood urea nitrogen, hemoglobin, hematocrit, and creatinine levels, random-
zation in the first or second half of study, atrial fibrillation ejection fraction,
ntiarrhythmic use, and in-hospital hypotension (systolic blood pressure 100 mm
g). †Covariates for rehospitalization: pulse pressure, hemoglobin, blood urea
itrogen, sodium, six-minute walk test (Y/N) and distance, supine heart rate, and the
ropensity score for beta-blocker use. ‡Covariates for death or rehospitalization: same
s rehospitalization plus age.
CI  confidence interval; OR  odds ratio.iated with the various outcomes assessed that were cap- *ured in the data collection. However, with a post-hoc
nalysis, it is possible that all factors that may have influ-
nced the decision to discontinue beta-blocker therapy may
ot have been captured in this study and that these factors
ay influence our results. The fact that some of the
utcomes may or may not have improved with beta-blocker
herapy (Table 4) could have been related to the number of
vents and the power to detect differences, but there was no
vidence of worsening outcomes with continued beta-
locker use.
Another concern with beta-blocker therapy in patients
ith decompensated HF is the potential for worsening
emodynamics and respiratory compromise. Although the
umber of patients needing intra-aortic balloon pump or
entilator support were too few to do adjusted analysis, in
nivariate analysis there was no suggestion of increased risk
uring the index hospitalization for either of these two
omplications with beta-blocker therapy. We can therefore
autiously conclude that continued beta-blocker therapy
mong these patients was not associated with worsening
utcomes and may actually improve them.
Medication prescription at the time of discharge has been
hown to be the strongest predictor of long-term adherence
o drug therapy (11,12). Discontinuation of medications
hat may not be absolutely necessary during hospital admis-
ion can have potentially inadvertent deleterious effects in
he long run, and the full benefit of therapy may not be
linically realized. To improve therapy for cardiovascular
edications at discharge, several national initiatives are
eing conducted by regulatory agencies and professional
ocieties (13–16). In our study, beta-blocker therapy was
ignificantly modified between admission and discharge
discontinued, changed to different beta-blocker, or 50%
ose reduction) among 82 patients; 54 of whom (66%) were






Length of stay (days of
initial hospitalization)
9.4  6.7 7.9  6.3 0.01†
Death, initial hospitalization (%) 2.4 1.5 0.48*
Death, 180 days (%) 24.4 16.0 0.03





Death, 180 days (%) 16.7 14.4 0.67





Death, 180 days (%) 23.1 13.7 0.01
Rehospitalization (%) 60.4 56.4 0.41
Death or rehospitalization,
180 days (%)




























































































2468 Butler et al. JACC Vol. 47, No. 12, 2006
Beta-Blocker Use in Decompensated HF June 20, 2006:2462–9ot prescribed these drugs at discharge. If beta-blocker
herapy is disrupted during hospitalization, it is possible that
t may not be initiated later. Another major problem in
iscontinuing or altering beta-blocker therapy is that their
p-titration in HF patients is a difficult and slow process. If
eta-blocker therapy is altered, even if beta-blockers are
ontinued, the patients may remain on suboptimal doses,
hereas higher doses of beta-blockers have been associated
ith incremental improvements in outcomes (1). Whether
r not beta-blocker therapy is continued during hospitaliza-
ion among HF patients is an important consideration for
hich little data exist. The present study suggests that
outinely discontinuing beta-blocker therapy among hospi-
alized HF patients may not be necessary.
We excluded four patients who were on beta-blockers on
dmission who died during the index hospitalization. These
atients were excluded because they cannot be classified in
he study definition, i.e., use of beta-blockers at admission
nd at discharge. However, this does raise an important
uestion regarding selection bias, that only the patients des-
ined to do well were included in the study. However, this was
ot the case. There were eight deaths overall during the index
ospitalization in the ESCAPE trial. Four of these were in
atients who were continued on beta-blocker therapy and four
ho were not. Proportionally speaking, only 4 of 268
atients on admission beta-blocker therapy (1.5%) died
ompared with 4 of 164 (2.4%) among those not on
eta-blocker therapy. Studying the patients who were on
eta-blockers on admission specifically, if we exclude these
our patients from the analysis, we see an outcome difference
death or rehospitalization rate at 6 months) in favor of
eta-blocker use (59.8% vs. 74.1%; p  0.053 unadjusted;
R 0.27 [95% CI 0.10 to 0.71]; p  0.01 adjusted). To
urther study the impact of these four deaths, we did two
ets of additional analyses: 1) counting these four patients
ho died as those who continued on beta-blocker therapy;
nd 2) counting these four as patients who did not continue
eta-blockers during hospitalization. If we consider them in
he group not continued on beta-blockers, the outcomes are
n favor of those who continued beta-blockers (59.8% vs.
5.9%; p  0.02; OR 0.22 [95% CI 0.08 to 0.60]; p  0.01
djusted). However, if we assume that all four deaths
ccurred in the group who were continued on beta-blocker
herapy, the overall outcomes still trend in favor of beta-
locker therapy (60.6% vs. 74.1%; p  0.06; OR 0.27 [95%
I 0.11 to 0.72]; p  0.01 adjusted). The overall results
ith respect to at least no worsening outcomes and possible
eneficial outcomes with beta-blocker therapy did not
hange based on the four hospital deaths.
tudy limitations. We do recommend being cautious with
eta-blockers in patients with decompensated HF. This
nvestigation, though provocative and suggestive of im-
roved outcomes with beta-blocker therapy in this group of
atients, is not definitive, because it was a retrospective
nalysis. Several important data are missing, the most
mportant of which is why beta-blocker therapy was discon-inued. Intolerance, symptomatic hypotension, bradycardia,
nd heart block are all recognized reasons for altering
eta-blocker therapy. The appropriateness of discontinuing
eta-blocker therapy cannot be commented on in this study.
lthough these data are adjusted for baseline differences
etween the two groups, they are retrospective in nature and
ne cannot be completely certain that some measured and
nmeasured differences between the two groups may not
ave influenced the outcomes. Other limitations include the
act that these patients were treated in a clinical trial that
ocused on centers with considerable experience in manag-
ng patients with advanced HF. Whether similar results can
e expected in the general group of patients is not known.
imilarly, beta-blockers were discontinued on admission in
minority of patients, which may not be the case in general
ractice outside of clinical trials. Either prospective ran-
omized studies or carefully designed registries are needed
o answer these questions more accurately.
onclusions. We found no worsening, but instead better,
F outcomes with continuation of beta-blocker therapy
mong hospitalized patients with decompensated HF. These
esults persisted even after controlling for differences between
he two groups, suggesting that routine discontinuation of
eta-blocker therapy on admission may not be necessary.
owever, the appropriateness of discontinuing beta-blocker
herapy in certain settings needs to be assessed prospectively.
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